Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Nare Hovhannisyan
20 Posts Not To Miss From ASCOQLTY26
The ASCO Quality Care Symposium 2026 (ASCOQLTY26) brought together oncologists, researchers, healthcare professionals, and patient advocates to discuss advances in cancer care quality, patient safety, and healthcare delivery. The meeting focused on improving patient outcomes, addressing disparities in cancer care, and sharing research aimed at strengthening oncology practice.
Parker Institute Investigators’ Startups Azalea and Medici Named to 2026 Endpoints 11
Two biotechnology companies co-founded by Parker Institute for Cancer Immunotherapy investigators, Azalea Therapeutics and Medici Therapeutics, have been named to the 2026 Endpoints 11, an annual selection recognizing promising startups across the biotechnology industry. The recognition brings attention to two approaches to cancer treatment: engineering cancer-fighting immune cells directly inside the body and developing highly personalized cancer therapies.
Breast Health Day 2026: Why Early Detection Matters and Why Screening Cannot Wait
Every year on October 15, Breast Health Day serves as a reminder that protecting breast health begins long before a cancer diagnosis. Observed during Breast Cancer Awareness Month, the day draws attention to breast cancer prevention, early detection, regular screening, and the importance of ensuring that women have access to timely and appropriate breast healthcare. Breast cancer remains one of the most significant public health challenges worldwide.
The True Strength of The UICC Lies with Its Members: C S Pramesh’s Vision for UICC
C S Pramesh, Director of Tata Memorial Hospital in Mumbai and Convener of India’s National Cancer Grid, is among the three candidates for President-elect of the Union for International Cancer Control (UICC) for the 2026–2028 term. A surgical oncologist, researcher, and global cancer health leader, Dr Pramesh currently serves on the Boards of Directors of UICC and ASCO.
Michael Bailey Named Next CEO of Verastem Oncology
Michael Bailey has been appointed President and Chief Executive Officer of Verastem Oncology, effective January 1, 2027, succeeding Daniel Paterson, who will retire after more than 35 years in the biopharmaceutical industry. The announcement, made on October 14, 2026, comes as the Boston-based biopharmaceutical company continues the commercialization of its approved ovarian cancer therapy and advances its clinical development programs targeting RAS/MAPK pathway-driven cancers.
OncoDaily Academy Introduces the First Module of its Six-part Programme on Immune Checkpoint Inhibitors
Immune checkpoint inhibitors have reshaped the treatment of advanced cancer. For a subset of patients, they deliver disease control measured in years, often persisting long after treatment has ended. For many others, that benefit never arrives. Some tumours show little response from the outset. Others respond, then progress. In several common cancers, first-generation checkpoint inhibitors have had limited impact. Explaining that gap has become one of the defining questions in oncology.
In Memoriam: Rachna Shroff, MD, MS, FASCO: A Life Dedicated to Advancing Cancer Care
The oncology community mourns the passing of Rachna Shroff, MD, MS, FASCO, an internationally respected gastrointestinal oncologist, clinician-scientist, and leading expert in cholangiocarcinoma whose contributions to cancer research and patient care have left a lasting mark on the field.
Daniel Boffa Begins Two-Year Term as Chair of the American College of Surgeons Commission on Cancer
Daniel Boffa, MD, MBA, chief of the Division of Thoracic Surgery and professor of thoracic surgery at Yale School of Medicine, has begun a two-year term as chair of the American College of Surgeons Commission on Cancer (CoC). An expert in cancer quality and outcomes, Boffa assumes the leadership position at a time when cancer care programs across the United States face increasing financial and workforce challenges.
Merck at ESMO 2026: Phase 3 mRNA, TROP2 ADC and Pembrolizumab Data Lead 90+ Abstracts
Merck will arrive at the ESMO Congress 2026 with more than 90 oncology abstracts spanning more than 20 tumor types, but the most closely watched presentations may offer a glimpse at what the company’s oncology portfolio looks like beyond its established pembrolizumab franchise.
15 Posts Not To Miss From DCLung26
The D.C. Lung Cancer Conference 2026 (DCLung26), held on October 10, 2026, in Washington, D.C., brought together international experts, clinicians, and multidisciplinary specialists to discuss recent advances in lung cancer diagnosis, treatment, and patient care.
David Kerr’s 8-Year-Old Daughter Interviews Him About Life as a Cancer Doctor
What does a cancer doctor’s working day look like through the eyes of an eight-year-old child? In an interview published by Medscape on February 1, 2019, David J. Kerr, Professor of Cancer Medicine, found himself answering questions from an interviewer who knew him not only as an oncologist, but also as her father.
Han-Kwang Yang Named Candidate for UICC Board of Directors 2026–2028
Han-Kwang Yang, President of the National Cancer Center Korea and Professor Emeritus at Seoul National University, has been named a candidate for the UICC Board of Directors for the 2026–2028 term. Based in Goyang, South Korea, Dr Yang is a surgical oncologist and internationally recognised expert in gastric cancer, with extensive experience spanning clinical research, cancer centre leadership, international professional societies, and surgical education.
OncoDaily Grand Rounds at ESMO 2026: Sarcoma Edition
The OncoDaily Grand Rounds at ESMO 2026: Sarcoma Edition will take place on October 23, 2026, from 1:00 PM to 4:00 PM, at the Novotel Madrid Feria and Airport in Madrid, Spain, bringing together leading specialists for a dedicated scientific discussion on developments in sarcoma research and clinical management.
OncoDaily Grand Rounds at ESMO 2026: Partners Unite for Sarcoma Research
The OncoDaily Grand Rounds at ESMO 2026: Sarcoma Edition will take place on October 23, 2026, from 1:00 PM to 4:00 PM, at the Novotel Madrid Feria and Airport in Madrid, Spain, bringing together leading specialists for a dedicated scientific discussion on developments in sarcoma research and clinical management.
From Liquid Biopsy to New Treatment Modalities: What to Expect at Northeast GI Oncology Congress 2026
OncoDaily’s Northeast GI Oncology Congress 2026 will take place November 19–21 in Boston, Massachusetts, bringing clinicians, researchers, and emerging investigators together to examine the science shaping the next era of gastrointestinal cancer care. Over three days, the congress will explore liquid biopsy, biomarker-directed treatment, immunotherapy, and new therapeutic modalities, connecting the biological rationale behind these approaches with the evidence needed to guide clinical decisions.
OCRF and News Corp Australia Launch “Over It” Campaign to Close the Ovarian Cancer Survival Gap
Ovarian Cancer Research Foundation (OCRF) and News Corp Australia have launched Over It, a national campaign calling on the Australian Government to increase investment in ovarian cancer research and address the disease’s persistent survival gap. Launched on October 11, 2026, the campaign seeks A$21 million annually for each of the next four years, totalling A$84 million, followed by sustained research investment until ovarian cancer survival exceeds 90%.
Rossella Blasi Appointed CEO of European School of Oncology
Rossella Blasi has been appointed Chief Executive Officer of the European School of Oncology (ESO), succeeding Alberto Costa, who has led the School since its foundation in 1982. Approved by ESO’s Board of Directors in Milan on October 8, 2026, the appointment marks a leadership transition for an institution that has trained more than 40,000 healthcare professionals worldwide.
GCOS 2026 Day 3 Highlights: From Cardiac Immunology to Translational Advances in Cardio-Oncology
The third and final day of the Global Cardio-Oncology Summit (GCOS 2026) took place on October 7, 2026, in Williamsburg, Virginia, United States, with a scientific program dedicated to basic and translational research in cardio-oncology. The day brought together international experts in cardiology, oncology, immunology, molecular biology, and clinical research to examine the biological mechanisms connecting cancer and cardiovascular disease.
MAMMÔ 2026 Day 2 Highlights: From Adjuvant Optimization to Metastatic Breast Cancer, ADCs and Precision Treatment
The second day of MAMMÔ 2026 brought together international breast cancer experts for an extensive scientific program addressing some of the most important challenges in contemporary breast cancer management. From optimizing adjuvant systemic therapy and overcoming resistance in metastatic disease to the expanding role of antibody-drug conjugates (ADCs), the discussions reflected the growing complexity of treatment selection across different breast cancer subtypes.
GCOS 2026 Second Half of Day 2: Life After Cancer and the Future of Cardioprotection
The second half of Day 2 at the Global Cardio-Oncology Summit (GCOS) 2026 examined the cardiovascular needs that continue after cancer treatment and the evidence informing preventive care. On October 6 in Williamsburg, Virginia, the afternoon program brought together reproductive health, long-term surveillance, biomarkers, radiation-associated valve disease, and pharmacological approaches to cardioprotection.
MAMMÔ 2026 Day 1 Highlights: From Early Detection and Precision Diagnostics to Treatment De-escalation and Global Breast Cancer Care
The MAMMÔ 2026 Global Breast Cancer Virtual Congress opened its scientific program with a comprehensive examination of the developments shaping breast cancer diagnosis, risk assessment, early-stage treatment, and access to care worldwide.
GCOS 2026 First Half of Day 2: Precision Exercise, Global Survivorship and New Approaches to Amyloidosis
The first half of Day 2 at the Global Cardio-Oncology Summit (GCOS) 2026, held on October 6 at the Williamsburg Lodge in Williamsburg, Virginia, examined how cardiovascular care can be incorporated into the daily management of patients with cancer. The morning moved from individualized exercise and rehabilitation to international approaches to survivorship, investigational amyloid-depleting therapies, and the cardiovascular toxicities of newer cancer treatments.
20 Posts Not To Miss From GCOS 2026
The Global Cardio-Oncology Summit (GCOS) 2026 took place from October 5–7, 2026, at the Williamsburg Lodge in Williamsburg, Virginia, USA. Held under the theme “Cardio-Oncology Innovation and Implementation for the Future,” the summit brought together international experts in cardiology, oncology, and related disciplines to discuss recent scientific advances, emerging research, and clinical strategies for improving cardiovascular care in patients with cancer.
Armenia Becomes First Country to Approve Agenus’ BOT+BAL for MSS Metastatic Colorectal Cancer
Armenia has become the first country in the world to grant marketing authorizations for Agenus’ botensilimab and balstilimab (BOT+BAL), marking the first approvals of either medicine globally. The authorizations cover their combined use in adults with microsatellite-stable (MSS) metastatic colorectal cancer without active liver metastases who have previously received available standard therapies, according to an Agenus press release issued on October 8, 2026.
Brazil Unlocked: Jennifer S. Buell on Brazil’s Role in Advancing Agenus and MiNK Therapeutics Clinical Programs
For small biotechnology companies, the ability to start studies efficiently, recruit patients, and generate reliable data can determine how quickly a development program advances. At Clinical Development in LATAM: Brazil Unlocked, Jennifer S. Buell, President and CEO of MiNK Therapeutics and Chair of the Executive Council at Agenus, described why Brazil has become an early consideration for both Agenus and MiNK Therapeutics.
GCOS 2026 Second Half of the Day 1: From Amyloidosis to the Ten Laws of Cardio-Oncology
The Second half of Day 1 at the Global Cardio-Oncology Summit (GCOS) 2026 continued the meeting’s focus on translating scientific progress into practical cardiovascular care for patients with cancer. Following the morning program, the afternoon moved through amyloidosis, one of the Summit’s signature lectures, updates from the International Cardio-Oncology Society, recognition of leadership in the field, and the Young Investigator Award program.
GCOS 2026 Day 1, Part 1: Global Perspectives, AI and the Research Shaping Cardio-Oncology
The Global Cardio-Oncology Summit (GCOS) 2026 opened on October 5 at the Williamsburg Lodge in Williamsburg, Virginia, bringing together an international, multidisciplinary community focused on one of the most rapidly evolving areas of cancer care.
PharmaMar Joins OncoDaily Grand Rounds at ESMO 2026: Sarcoma Edition as Foundational Partner
PharmaMar has joined the OncoDaily Grand Rounds at ESMO 2026: Sarcoma Edition as a Foundational Partner. The meeting will take place on October 23, 2026, in Madrid, bringing together leading sarcoma specialists during the ESMO 2026 Congress. The Grand Rounds will be held from 1:00 PM to 4:00 PM at the Novotel Madrid Feria and Airport, located just two minutes from IFEMA Madrid.
20 Posts Not To Miss From IGCS 2026
The 2026 Annual Global Meeting of the International Gynecologic Cancer Society (IGCS 2026) brought the global gynecologic oncology community together from October 1–3, 2026, at the Palais des Congrès de Montréal in Montréal, Canada.
Northeast GI Oncology Congress 2026: Bringing the GI Oncology Community Together
OncoDaily’s Northeast GI Oncology Congress 2026 will take place November 19–21 in Boston, Massachusetts, bringing clinicians, researchers, early-career investigators, and patient advocates into a shared discussion about the future of gastrointestinal cancer care. Over three days, the congress will connect scientific discovery with clinical practice, exploring how advances across GI cancers can inform treatment decisions, research priorities, and the patient experience.
Imugene Reports New Responses With Azercabtagene Zapreleucel Plus BTK Inhibitor in Phase 1b Blood Cancer Trial
Imugene has reported one additional complete response in mantle cell lymphoma and one partial response in chronic lymphocytic leukemia in the BTK inhibitor combination cohort of its ongoing Phase 1b trial of azercabtagene zapreleucel (azer-cel). The October 5, 2026 announcement adds results from four patients assessed at Day 28, bringing the combination cohort to seven evaluable patients. All patients enrolled in this cohort had previously received and progressed on BTK inhibitor therapy.
Zipporah Ali Named Candidate for UICC Board of Directors 2026–2028
Zipporah Ali, a palliative care physician and public health specialist based in Nairobi, Kenya, has been named a candidate for the Union for International Cancer Control (UICC) Board of Directors for the 2026–2028 term. Dr Ali has more than three decades of experience in cancer care, palliative care, advocacy, public health, and health policy.
Brazil Unlocked: Brazil’s Clinical Research Ecosystem
Identifying a large patient population is only the beginning of clinical trial recruitment. Sponsors also need to understand where eligible patients receive care, how referrals happen, and whether research teams can sustain quality as enrollment grows. Those questions shaped the final block of Clinical Development in LATAM: Brazil Unlocked, organized by ODC Life Sciences with MassBio on September 24, 2026, in Cambridge, Massachusetts, and online.
Brazil’s Clinical Trial Reforms Take Center Stage at Brazil Unlocked
More predictable regulatory review and a single ethical assessment for multicenter studies are changing how sponsors plan clinical trials in Brazil. At Clinical Development in LATAM: Brazil Unlocked, speakers examined the reforms behind that shift and the work still needed to implement them consistently. Organized by ODC Life Sciences with MassBio on September 24, 2026, at MassBio Hub in Cambridge, Massachusetts, and online, the event was covered by OncoDaily.
Anu Agrawal Named Candidate for UICC Board of Directors 2026–2028
Anu Agrawal (Anurag K. Agrawal), Vice President of Global Cancer Support at the American Cancer Society (ACS), has been named a candidate for the Union for International Cancer Control (UICC) Board of Directors for the 2026–2028 term. A pediatric hematologist-oncologist and bone marrow transplantation physician, Dr Agrawal brings experience spanning clinical oncology, global cancer support, patient navigation, quality improvement, and health disparities.
Brazil Unlocked: Biotech Leaders and Investors Make the Case for Earlier Clinical Trial Planning
Brazil’s role in global clinical development should begin when a study is being designed, rather than when recruitment elsewhere falls behind. That was the central argument of the opening session at Clinical Development in LATAM: Brazil Unlocked, organized by ODC Life Sciences with MassBio on September 24, 2026, at MassBio Hub in Cambridge, Massachusetts, and online.
AstraZeneca and Daiichi Sankyo Partner with Summit Therapeutics to Study Datopotamab Deruxtecan and Ivonescimab
A new clinical collaboration will explore whether combining a TROP2-directed antibody-drug conjugate with a bispecific immunotherapy can expand treatment possibilities across solid tumors. AstraZeneca and Daiichi Sankyo have entered into a clinical trial collaboration with Summit Therapeutics to evaluate datopotamab deruxtecan in combination with ivonescimab.
OncoDaily Heads to Dubai to Cover the 7th EOS Annual Conference
On 3–4 October 2026, the 7th Emirates Oncology Society Annual Conference 2026 will bring that conversation to the InterContinental Hotel, Dubai Festival City, UAE. Oncology specialists, researchers, healthcare professionals, and industry representatives will gather for two days of scientific exchange, education, and professional collaboration.
AACR 2026: Why Do KRAS G12D Pancreatic Tumors Respond Differently? Wungki Park on New Setidegrasib Data
New translational analyses of setidegrasib, Astellas’ investigational KRAS G12D-targeted protein degrader, are providing a closer look at why pancreatic cancers driven by the same mutation may respond differently to treatment.
Kathleen Schmeler Named Candidate for UICC Board of Directors 2026–2028
Dr Kathleen Schmeler, Associate Vice President of Global Oncology and Professor of Gynecologic Oncology at MD Anderson Cancer Center, has been named a candidate for the UICC Board of Directors for the 2026–2028 term. Dr Schmeler currently serves on the UICC Board and is seeking a second term. She is among 24 candidates running for 14 Board seats. UICC full-member organisations will elect the new Board during the 2026 UICC General Assembly, which will take place virtually on October 20, 2026.
Immuno 2026 Day 7 Highlights: Global Access to Immunotherapy and Education
The seventh and final day of the Immuno 2026 Global Virtual Congress on Immuno-Oncology, held on September 30, 2026, focused on global access to immunotherapy and education. The sessions looked at how scientific advances can become safe, affordable treatments for patients everywhere. They covered in vivo CAR T-cell therapy, cell therapy programs in Latin America, immunotherapy in resource-limited settings, the hidden toxicities of CAR T cells, and the WHO’s view of global access.
Inside Setidegrasib’s Phase 3 Development: Targeting KRAS G12D Through Protein Degradation
Astellas announced that the first patient has been dosed in a Phase 3 trial evaluating setidegrasib, an investigational KRAS G12D-targeted protein degrader, against docetaxel in previously treated advanced non-small cell lung cancer (NSCLC). The study includes patients with KRAS G12D-mutated, locally advanced unresectable or metastatic NSCLC whose disease has progressed on or after platinum-based chemotherapy and checkpoint inhibitor therapy.
GC-OS 2026: What Not to Miss at the Global Cardio-Oncology Summit
Cancer treatment is becoming more effective, more personalized, and increasingly complex for the heart. As patients live longer and new therapies reshape oncology, clinicians are facing a growing set of cardiovascular questions: How should cardiotoxicity be predicted? Which patients need closer surveillance? Can cardiovascular complications be prevented before they appear? And how should care continue years after cancer treatment ends?
Christian Ntizimira Named Candidate for UICC Board of Directors 2026–2028
Christian Ntizimira, Founder and Executive Director of the African Centre for Research on End-of-Life Care (ACREOL Global) in Rwanda, has been named a candidate for the Union for International Cancer Control (UICC) Board of Directors for the 2026–2028 term. UICC lists Dr Ntizimira among the 24 candidates competing for 14 Board seats. UICC The new Board will be elected by UICC full-member organisations at the 2026 UICC General Assembly, which will take place virtually on October 20, 2026.
Introducing OncoDaily Academy: A New Global Platform for Oncology Education
A new initiative by OncoDaily, the OncoDaily Academy, will connect clinicians with expert-led learning experiences across the evolving landscape of cancer care. The field of oncology is advancing at an unprecedented pace. With discoveries, emerging treatment approaches, and rapidly evolving standards of care, continuous education has become essential for healthcare professionals worldwide.
Pfizer to Present 45 Abstracts at ESMO 2026, With Data in Breast, Genitourinary, Lung Cancers and Melanoma
Pfizer announced on September 28 that it will present data from 45 abstracts at the European Society for Medical Oncology (ESMO) Congress 2026, held October 23-27 in Madrid. The abstracts include company-sponsored, investigator-sponsored, and collaborative studies. Eleven will be oral presentations. The company said the program focuses on breast cancer, genitourinary cancers, and lung cancer.
Christopher Jackson Named Candidate for UICC Board of Directors 2026–2028
Christopher Jackson, Professor of Medical Oncology at the University of Otago and National Clinical Lead for Cancer Services in New Zealand, has been named a candidate for the Union for International Cancer Control (UICC) Board of Directors for the 2026–2028 term.
Teva Receives U.S. FDA Approval for Denosumab Biosimilar for Oncology Indications
Teva Pharmaceutical Industries announced that the U.S. Food and Drug Administration (FDA) has approved denosumab-adet, a biosimilar to denosumab, across all indications of the reference product. The approval expands Teva’s biosimilar portfolio in oncology and bone health, providing a new treatment option for patients requiring denosumab-based therapy.
Melissa Lopez Varon Advances Breast and Cervical Cancer Prevention Through Collaborative Training
Melissa Lopez Varon, Director of Global Oncology at UT MD Anderson, shared on LinkedIn: “This weekend, we had the privilege of bringing together 25 participants from across Texas for an integrated breast and cervical cancer prevention and early detection & patient navigation training.
Nirmala Bhoo Pathy Reflects on World Cancer Congress 2026 and Prepares for APOCP Conference
Nirmala Bhoo Pathy, Professor at the University of Malaya and Adjunct Professor at Kasturba Medical College, Manipal, shared on LinkedIn: “Our party is simply just changing venues. What a wonderful few days at the World Cancer Congress 2026 in Hong Kong! One of the real highlights was our Lancet Oncology Commission session on the Human Crisis in Cancer with Gary Rodin, Richard Sullivan, Wendy Lam and Mac Skelton. It was lovely to see OncoDaily pick up the session.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Nare
Contact Nare, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack